Only a small percentage of cancer patients have access to genomic biomarker information that could help match them with targeted treatments demonstrated to improve outcomes. By working with local laboratories to insource NGS oncology assays, we support your efforts to deliver equitable access to precision oncology.
Through Project ACTT, Imagia Canexia Health is speeding up cancer testing for targeted treatment selection during and beyond COVID-19 through a minimally invasive circulating tumor DNA (ctDNA) assay. The assay, which requires a blood sample, is available as an alternative to some surgical tissue biopsies for patients with advanced lung or breast cancer in Canada.
We pair the latest advances in oncology with machine learning to provide cancer researchers and professionals with the insights needed to make informed decisions.
“We have found the FIND-IT assay to be a reliable, quick and cost-effective tool for identifying driver mutations in fixed tissue samples from across Australia. This has had direct implications for identifying patients suitable for targeted therapies, especially those with lung cancer, colorectal cancer and melanoma. However, the scope of the test is such that there is also interest in the panel for patients with a variety of other cancers, including breast and endometrial cancers.” Professor Graeme Suthers, Sonic Genetics
Imagia Canexia Health’s Find It & Fusions panels detect mutations and gene fusion events in solid tumor tissue. Tissue profiling can be used to help inform treatment decisions or predict progression of cancer based on somatic mutations found in the tumor.
Imagia Canexia Health’s Follow It panel detects mutations in plasma. Plasma profiling (a type of liquid biopsy) can be used to help tailor treatment, monitor cancer progression, or detect treatment resistance.
Make more informed treatment decisions by using detailed results for therapeutic recommendations and expertly curated clinical trials information provided in our comprehensive reporting software.
Perform sophisticated NGS oncology profiling right from your laboratory without the large upfront investment. Pairing our cloud-based analytics, interpretation, and reporting platform allows partner labs access to our proprietary informatics software suite. This suite covers the full stack of molecular and computational quality assurance, genome analytics, mutation interpretation, and report generation.
June 5, 2023
To discuss the development of the Endometrial ProMisE Molecular Classifier, and the new NSMP study further, we are delighted to have Dr. Jessica McAlpine and Dr. Amy Jamieson, esteemed gynecological cancer surgeons at Vancouver General Hospital, who have been instrumental in the development and implementation of this innovative tool.
May 15, 2023
We were grateful for the opportunity to attend and present at the AACR Annual Meeting last week, where three of our scientists highlighted some of the exciting work happening in our Vancouver lab.
March 28, 2023
Imagia Canexia Health announced that three abstracts highlighting the company’s new learnings and tools will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, Florida.
Contact us today to learn about our end-to-end solution, from mutation identification to auto-generated clinical reports.